{"id":"https://openalex.org/W7225647565","doi":"https://doi.org/10.1007/s40199-026-00692-0","title":"Efficacy and safety of the cladribine, idarubicin, and cytarabine regimen for treating acute myeloid leukemia: a systematic review and single-arm meta-analysis","display_name":"Efficacy and safety of the cladribine, idarubicin, and cytarabine regimen for treating acute myeloid leukemia: a systematic review and single-arm meta-analysis","publication_year":2026,"publication_date":"2026-11-09","ids":{"openalex":"https://openalex.org/W7225647565","doi":"https://doi.org/10.1007/s40199-026-00692-0","pmid":"https://pubmed.ncbi.nlm.nih.gov/43002273"},"language":"en","primary_location":{"id":"doi:10.1007/s40199-026-00692-0","doi":"https://doi.org/10.1007/s40199-026-00692-0","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s40199-026-00692-0","pdf_url":null,"source":{"id":"https://openalex.org/S47297815","display_name":"DARU Journal of Pharmaceutical Sciences","issn_l":"1560-8115","issn":["1560-8115","2008-2231"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"DARU Journal of Pharmaceutical Sciences","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100568501","display_name":"Yichen Xu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Yichen Xu","raw_affiliation_strings":["School of Life Sciences and Materials Chemistry, College of Science & Technology Ningbo University, Ningbo, China. 2946326557@qq.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Life Sciences and Materials Chemistry, College of Science & Technology Ningbo University, Ningbo, China. 2946326557@qq.com","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161359955","display_name":"Shuai Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27781120","display_name":"Wenzhou Medical University","ror":"https://ror.org/00rd5t069","country_code":"CN","type":"education","lineage":["https://openalex.org/I27781120"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Shuai Chen","raw_affiliation_strings":["The Second Clinical Medical College, Wenzhou Medical University, Wenzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Second Clinical Medical College, Wenzhou Medical University, Wenzhou, China","institution_ids":["https://openalex.org/I27781120"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5161316803","display_name":"Ruolin Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27781120","display_name":"Wenzhou Medical University","ror":"https://ror.org/00rd5t069","country_code":"CN","type":"education","lineage":["https://openalex.org/I27781120"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ruolin Zhang","raw_affiliation_strings":["The Second Clinical Medical College, Wenzhou Medical University, Wenzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Second Clinical Medical College, Wenzhou Medical University, Wenzhou, China","institution_ids":["https://openalex.org/I27781120"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5100568501"],"corresponding_institution_ids":[],"apc_list":{"value":4590,"currency":"USD","value_usd":4590},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.972000002861023},{"id":"https://openalex.org/keywords/cladribine","display_name":"cladribine","score":0.9580000042915344},{"id":"https://openalex.org/keywords/idarubicin","display_name":"idarubicin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/newly-diagnosed-aml","display_name":"newly diagnosed AML","score":0.8199999928474426},{"id":"https://openalex.org/keywords/relapsed-refractory-aml","display_name":"relapsed/refractory AML","score":0.9980000257492065},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.9950000047683716},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9589999914169312},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.6190000176429749},{"id":"https://openalex.org/keywords/severe-infection","display_name":"serious infections","score":0.621999979019165},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.49000000953674316},{"id":"https://openalex.org/keywords/hemorrhage","display_name":"hemorrhage","score":0.5839999914169312},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.7730000019073486},{"id":"https://openalex.org/keywords/high-risk-aml","display_name":"high-risk AML","score":0.7519999742507935},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.6050000190734863},{"id":"https://openalex.org/keywords/allogeneic-stem-cell-transplantation","display_name":"allogeneic stem cell transplantation","score":0.6200000047683716}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8884000182151794},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.7175999879837036},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6607000231742859},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6169999837875366},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5892999768257141},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47279998660087585},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.446399986743927},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.44350001215934753},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.42250001430511475},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4223000109195709},{"id":"https://openalex.org/C2778623314","wikidata":"https://www.wikidata.org/wiki/Q412685","display_name":"Gemtuzumab ozogamicin","level":5,"score":0.364300012588501},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3440000116825104},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.33320000767707825},{"id":"https://openalex.org/C3018657049","wikidata":"https://www.wikidata.org/wiki/Q1595418","display_name":"Complete remission","level":3,"score":0.3330000042915344},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.31679999828338623},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3084000051021576},{"id":"https://openalex.org/C189708586","wikidata":"https://www.wikidata.org/wiki/Q1504425","display_name":"Systematic review","level":3,"score":0.29670000076293945},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.2953000068664551},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.29269999265670776},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.29109999537467957},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.28619998693466187},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.26579999923706055},{"id":"https://openalex.org/C188313352","wikidata":"https://www.wikidata.org/wiki/Q119697","display_name":"Off-label use","level":2,"score":0.258899986743927},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.2565999925136566},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.2515000104904175},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.25119999051094055},{"id":"https://openalex.org/C179755657","wikidata":"https://www.wikidata.org/wiki/Q58702","display_name":"Mortality rate","level":2,"score":0.25049999356269836}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015255","descriptor_name":"Idarubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D015255","descriptor_name":"Idarubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D015255","descriptor_name":"Idarubicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017338","descriptor_name":"Cladribine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017338","descriptor_name":"Cladribine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D017338","descriptor_name":"Cladribine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1007/s40199-026-00692-0","doi":"https://doi.org/10.1007/s40199-026-00692-0","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s40199-026-00692-0","pdf_url":null,"source":{"id":"https://openalex.org/S47297815","display_name":"DARU Journal of Pharmaceutical Sciences","issn_l":"1560-8115","issn":["1560-8115","2008-2231"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"DARU Journal of Pharmaceutical Sciences","raw_type":"journal-article"},{"id":"pmid:43002273","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/43002273","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1839845827","https://openalex.org/W2017044005","https://openalex.org/W2047357233","https://openalex.org/W2061876001","https://openalex.org/W2114915163","https://openalex.org/W2116475791","https://openalex.org/W2246320611","https://openalex.org/W2288894655","https://openalex.org/W2530650859","https://openalex.org/W2587825292","https://openalex.org/W2772526125","https://openalex.org/W2793405456","https://openalex.org/W2883399820","https://openalex.org/W2944112179","https://openalex.org/W3006597436","https://openalex.org/W3092377143","https://openalex.org/W3118615836","https://openalex.org/W3128220341","https://openalex.org/W3176370909","https://openalex.org/W4231346141","https://openalex.org/W4280640050","https://openalex.org/W4282925423","https://openalex.org/W4366977509","https://openalex.org/W4386209204","https://openalex.org/W4402452356","https://openalex.org/W4407966812","https://openalex.org/W4409236097","https://openalex.org/W4414978679"],"related_works":["https://openalex.org/W4388466895","https://openalex.org/W3190557784","https://openalex.org/W4407966812","https://openalex.org/W4410541152","https://openalex.org/W4409236097","https://openalex.org/W7133510040","https://openalex.org/W3006146898","https://openalex.org/W2227661629","https://openalex.org/W2246320611","https://openalex.org/W2947402617"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-11-10T00:00:00"}